WeVote
Log In

Bill

Bill

HB 4673

Relating to the effect of certain reductions in a health benefit plan enrollee's out-of-pocket expenses for prescription drugs that are essential health benefits on the enrollee's cost-sharing requirements.

89th Legislature (2025) Introduced by Venton Jones

Texas bill prevents insurers from offsetting prescription drug cost reductions by raising other out-of-pocket expenses for enrollees.

Referred to Insurance
#contractors&subcontractors(s2563) #insurance--health&accident(i0422) #medicine&prescriptiondrugs(s7338) #pharmacybenefitmanagers(s0648)
0
WeVote Research Nonpartisan
Bill Summary · HB 4673

Legislative bill overview

HB 4673 modifies how health insurers must treat reductions in out-of-pocket expenses for prescription drugs classified as essential health benefits. The bill appears to establish rules preventing insurers from shifting reduced drug costs to other cost-sharing obligations, ensuring that prescription drug savings directly benefit enrollees rather than being offset by higher deductibles or copayments elsewhere.

Why is this important

Prescription drug costs represent a significant burden for many Texans, and how insurers account for drug cost reductions directly affects enrollee affordability. This bill addresses whether pharmaceutical assistance programs, manufacturer rebates, or other cost-reduction mechanisms genuinely lower enrollee expenses or simply allow insurers to increase other cost-sharing requirements. The outcome determines real financial protection for patients managing chronic conditions.

Potential points of contention

  • Insurer flexibility vs. consumer protection: Insurers may argue they need cost-shifting flexibility to maintain plan sustainability, while consumer advocates contend this practice negates intended drug cost savings
  • Definitional precision: The bill's effectiveness depends heavily on how "reductions" and "cost-sharing requirements" are precisely defined in final language, which remains unclear from the current bill text
  • Market impact: Insurance carriers may adjust premium rates upward if prevented from offsetting drug savings through other cost-sharing mechanisms, potentially affecting overall plan costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.